Access to Genetic Counselor Services Act of 2025
Summary
HR 6280, the Access to Genetic Counselor Services Act of 2025, is an early-stage bill that would expand Medicare Part B coverage to include genetic counseling services starting January 1, 2027. The bill has no direct funding authorization and is in the earliest legislative stages, with zero near-term market impact. Medicare Advantage insurers face a negligible incremental cost, but the bill's primary beneficiaries are genetic counselors, not publicly traded companies.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR 6280 is an early-stage bill with no committee action in six months; passage probability is low.
- 2.The bill authorizes no funding; it only expands Medicare Part B coverage to include genetic counseling services.
- 3.No publicly traded company is a direct beneficiary; Medicare Advantage insurers face negligible incremental costs.
- 4.The effective date of January 1, 2027 means any impact is at least 7 months away even if the bill were to pass.
Market Implications
The bill has no near-term market implications. It is stuck in committee with no momentum. Even if passed, the coverage expansion is small relative to the $1 trillion+ Medicare program. Investors should ignore this bill until it shows signs of legislative progress, such as a committee markup or CBO score.
Full Analysis
-
What happened: On November 21, 2025, Representative Adrian Smith (R-NE) introduced HR 6280, the Access to Genetic Counselor Services Act of 2025. The bill was referred to both the Energy and Commerce Committee and the Ways and Means Committee. As of today (May 20, 2026), the bill remains in committee with no further action. A companion bill, S3607, was introduced in the Senate and referred to the Finance Committee. The bill is in the earliest legislative stage.
-
The money trail: This bill does not authorize or appropriate any specific funding. It amends the Social Security Act to define 'covered genetic counseling services' and 'genetic counselor' for Medicare Part B purposes. The mechanism is a coverage expansion, not a funding allocation. Actual Medicare spending would increase only to the extent that genetic counselors bill for services provided to beneficiaries. The Congressional Budget Office would estimate the cost, but no estimate is publicly available. The effective date is January 1, 2027, meaning no spending would occur before then.
-
Structural winners and losers: The direct beneficiaries are genetic counselors themselves, who gain direct Medicare billing privileges. No publicly traded company is a pure-play genetic counseling provider. Large diagnostic testing companies like Quest Diagnostics ($DGX) and LabCorp ($LH) could see incremental volume if genetic counseling referrals increase testing utilization, but the link is indirect and the impact is small. Medicare Advantage insurers (, $HUM, $CI) face a modest new coverage requirement that is negligible relative to their total medical costs. The bill does not affect pharmaceutical companies, device makers, or other healthcare sectors.
-
No real market data is provided for any ticker. The bill's early stage and lack of funding make market impact analysis premature.
-
Timeline: The bill must pass both the House Energy and Commerce and Ways and Means Committees, then the full House, then the Senate (or the companion S3607 must pass), and be signed by the President. With no committee action in six months, the bill has stalled. Even if passed, the effective date is January 1, 2027, providing a long runway. Passage probability is low in the current Congress given the early stage and lack of momentum.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Same as above: Medicare Part B coverage expansion for genetic counseling services.
Who must act
CMS and MACs must implement billing for genetic counselors under Part B.
What happens
Humana's Medicare Advantage plans must cover genetic counseling services for its ~5 million Medicare Advantage members, adding a small incremental medical cost.
Stock impact
Humana's Medicare Advantage business is its primary revenue driver (~$100B annual revenue). The added cost of genetic counseling coverage is negligible relative to total medical costs, and any benefit from early detection is uncertain. Net impact is neutral.
What the bill does
Same as above: Medicare Part B coverage expansion for genetic counseling services.
Who must act
CMS and MACs must implement billing for genetic counselors under Part B.
What happens
Cigna's Medicare Advantage plans (through Cigna-HealthSpring) must cover genetic counseling services for its ~1 million Medicare Advantage members, adding a small incremental medical cost.
Stock impact
Cigna's Medicare Advantage business is a smaller portion of its ~$200B annual revenue. The added cost is negligible. Net impact is neutral.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Improving Seniors’ Timely Access to Care Act of 2025
Protecting Seniors and Stopping Fraudsters Act
Fair Care Act of 2026
HELP Copays Act
A bill to amend title XVIII of the Social Security Act to protect against high out-of-pocket expenditures for Medicare fee-for-service benefits, and to amend titles XVIII and XIX of the Social Security Act to enhance programs that protect low-income Medicare beneficiaries.
To provide for civil monetary penalties for violations of mental health parity requirements.
IDA Act of 2026
January 6th Law Enforcement Heroes Compensation Fund Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →